Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.
- 1 April 1987
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 75 (4), 785-791
- https://doi.org/10.1161/01.cir.75.4.785
Abstract
The relationship between debrisoquine metabolic phenotype and the pharmacokinetics and pharmacodynamics of propafenone was studied in 28 patients with chronic ventricular arrhythmias (22 extensive metabolizers [EMs] and six poor metabolizers [PMs] of debrisoquine). EMs were characterized by a shorter propafenone elimination half-life (5.5 +/- 2.1 vs 17.2 +/- 8.0, p less than .001), lower average plasma concentration (Cp) (1.1 +/- 0.6 vs 2.5 +/- 0.5 ng/ml/mg daily dosage, p less than .001), and higher oral clearance (1115 +/- 1238 vs 264 +/- 48 ml/min, p less than .001). The active metabolite 5-hydroxypropafenone, assayed in 12 patients, was identified in nine of 10 EMs but in neither of the PMs. A lower incidence of central nervous system side effects was noted in EMs (14% vs 67%, p less than .01). The magnitude of QRS widening at any given propafenone Cp was greater in EMs than PMs. There was no significant difference between EMs and PMs in effective propafenone dose or frequency of antiarrhythmic response. Inhibition of debrisoquine 4-hydroxylation by propafenone was demonstrated both in vivo and in a human liver microsomal system in vitro. We conclude that propafenone is metabolized via the same cytochrome P-450 responsible for debrisoquine's 4-hydroxylation, and that its pharmacokinetics and concentration-response relationships and the incidence of central nervous system side effects are different in patients of different debrisoquine metabolic phenotype.Keywords
This publication has 19 references indexed in Scilit:
- Effect of propafenone in the wolff-parkinson-white syndrome: Electrophysiologic findings and long-term follow-upThe American Journal of Cardiology, 1984
- Propafenone for refractory ventricular arrhythmias: Correlation with drug plasma levels during long-term treatmentThe American Journal of Cardiology, 1984
- Effect of propafenone in patients with stable ventricular arrhythmiasAmerican Heart Journal, 1984
- Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolismBiochemistry, 1984
- Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardiaJournal of the American College of Cardiology, 1984
- Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardiaThe American Journal of Cardiology, 1983
- Purification and characterization of six cytochrome P-450 isozymes from human liver microsomesBiochemistry, 1983
- Propafenon und Lidoflazin bei chronischem Vorhofflimmern und -flatternDeutsche Medizinische Wochenschrift (1946), 1978
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINEThe Lancet, 1977
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977